menu
Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies -'Roots Analysis'
Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies -'Roots Analysis'
In recent years, the concept of STING pathway targeting therapeutics has generated a lot of enthusiasm within the medical science community. The growing popularity of this therapeutic technique has not only garnered the interest of several medical researchers

In recent years, the concept ofSTING pathway targeting therapeutics has generated a lot of enthusiasm withinthe medical science community. The growing popularity of this therapeutictechnique has not only garnered the interest of several medical researchers (reflectedin the increasing volume of scientific literature (1,000+ articles publishedsince 2015) on this subject), but also industry stakeholders focused ondrug development (evident in the growing number of clinical trials and thegrants awarded for STING focused projects in the recent past).

 

To order this 310+page report, which features 170+ figures and 200+ tables, please visit this link

 

The USD 2.8 billion(by 2030) financial opportunity within the STING pathway targeting technologiesmarket has been analysed across the following segments:

§  Types of Payment

§  Upfront Payments

§  Milestone Payments

 

§  Typeof STING Modulator

§  Agonist

§  Antagonist

 

§  KeyTherapeutic Area(s)

§  OncologicalDisorders

§  InflammatoryDisorders

§  InfectiousDiseases

§  Others

 

§  Routeof Administration

§  Intratumoral

§  Intravenous

§  Oral

§  Subcutaneous

§  Others

 

§  Typeof Molecule

§  Non-nucleotide

§  CyclicDinucleotide

§  LiveBiotherapeutics

§  OncolyticPeptides

§  SyntheticPeptides

§  Others

 

§  KeyGeographical Regions

§  NorthAmerica

§  Europe

§ Asia-Pacific 

 

The STINGPathway Targeting Therapeutics and Technologies, 2020-2030 report features thefollowing companies, which we identified to be key players in this domain:

§  AduroBiotech

§  BristolMyers Squibb

§  Eisai

§  GlaxoSmithKline

§  ImmuneSensorTherapeutics

§  Merck

§  Noxopharm

§  SpringBank Pharmaceuticals

§  Synlogic

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. STING Pathway TargetingTherapeutics: Current Market Landscape

5. STING Pathway TargetingTechnologies: Current Market landscape

6. Company Profiles

7. Academic Grant Analysis 

8. STING Related Initiatives ofBig Pharmaceutical Players

9. Start-up Health Indexing

10. Publication Analysis

11. Partnerships andCollaborations

 

12. Funding and InvestmentAnalysis

13. Market Sizing andOpportunity Analysis

14. Executive Insights

 

15. Concluding Remarks

 

16. Appendix 1: Tabulated Data

 

17. Appendix 2: List ofCompanies and Organizations

 

To purchase a copy,please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com